Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fábio Cardoso Borges
Observed names:
Cardoso Borges, Fábio,
Fabio Cardoso Borges
Institutions:
European Organisation for Research and Treatment of Cancer,
European Organisation for Research and Treatment of Cancer,
KU Leuven
Observed institutions:
European Organisation for Research and Treatment of Cancer,
Instituto Português de Oncologia Francisco Gentil,
European Organisation for Research and Treatment of Cancer,
KU Leuven
ORCID:
0000-0001-8496-9211
Observed ORCID:
0000-0001-8496-9211
OpenAlex ID:
A5114329689
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer
2025
·
Fábio Cardoso Borges
, Winette T A van der Graaf
, et al.
·
The Lancet Oncology
·
14
Do regulations and policies undermine the social value of independent academic research?
2024
·
Denis Lacombe
, Fábio Cardoso Borges
·
European Journal of Cancer
·
6
PDF
Synergizing Needs Assessments and Patient Preference Studies for Enhanced Patient-Centered Decision Making in Healthcare
2025
·
Elise Schoefs
, Alice Vanneste
, et al.
·
Value in Health
·
4
PDF
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum
2026
·
Denis Lacombe
, Fábio Cardoso Borges
, et al.
·
Journal of Cancer Policy
·
3
Pragmatism in academic gastrointestinal cancer clinical trials: An analysis of trials conducted by the EORTC gastrointestinal tract cancer group and the unicancer gastrointestinal group
2026
·
Hannah C. Puhr
, Fabio Cardoso Borges
, et al.
·
European Journal of Cancer
An Implementation Roadmap to Accelerate Academic Clinical Cancer Research in Portugal: A Multistakeholder Perspective
2026
·
Ana Sofia V. Carvalho
, Fábio Cardoso Borges
, et al.
·
Acta Médica Portuguesa
PDF
A Multistakeholder Perspective
2026
·
Ana, Ana Sofia
, Cardoso Borges, Fábio
, et al.
·
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
HPR226 Uncertainties in Regulatory Benefit-Risk Decision Making for Innovative Anticancer Therapies: Preliminary Results From a 2011-2024 Review of Extensions of Indications
2025
·
Fábio Cardoso Borges
, Luigi Lim
, et al.
·
Value in Health
Show more works
View as search
Works count:
10
Citation count:
27
H-index:
3
I10-index:
1
Year
Topic
Type